

The Board of Pharmacy has received notice of the following product recall. The Board strongly encourages pharmacies to immediately review their quality assurance and recall policies and procedures to determine if any corrective action is required.

Description	Lot # and Exp Date	NDC	UPC
LIDOC+PRIL CRM 2.5% ACTA30GM@	16820 04/30/24; 16787 04/30/24; 16786 04/30/24; 16627 04/30/24; 16506 03/31/24; 16505 03/31/24; 16469 02/29/24; 16412 02/29/24; 16291 01/31/24; 16258 12/31/22; 16257 12/31/22; 16256 02/29/24; 16255 11/30/22	00591207030	30591207030
LIDOC+PRIL CRM 2.5%ACTA5X5GM	16469 02/29/24; 16291 01/31/24	00591207072	30591207072

Teva is recalling the above items/lots due to stability testing to support these products on the market has been terminated due to the closure of Teva's third party manufacturer of this product. This recall is to the retail level. Affected product started shipping January 4, 2021.